PI3K pathway-directed therapeutic strategies in cancer

Roshan Agarwal, Mark Carey, Bryan Hennessy, Gordon B. Mills

Research output: Contribution to journalReview articlepeer-review

47 Scopus citations


PI3K pathway signaling is the focus of intensive oncology drug-development programs at several academic institutions and pharmaceutical companies. With several drugs that target different parts of the pathway in early clinical trials, this review presents evidence demonstrating that the PI3K pathway represents a suitable target for cancer drug development, discusses therapeuticstrategies for targeting the pathway, and highlights the status of drugs currently in development.

Original languageEnglish (US)
Pages (from-to)615-628
Number of pages14
JournalCurrent Opinion in Investigational Drugs
Issue number6
StatePublished - Jun 2010
Externally publishedYes


  • Akt
  • Cancer
  • Drug development
  • Growth factor signaling
  • PI3K
  • Phase I clinical trial
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'PI3K pathway-directed therapeutic strategies in cancer'. Together they form a unique fingerprint.

Cite this